Acacia Pharma Announces Amendment of its Investment Agreement with Cosmo Pharmaceuticals for BYFAVO™
€5 million commercialization milestone to be paid by Acacia Pharma to Cosmo in New Ordinary Shares
BYFAVO expected to be launched in the United States within the coming weeks
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014.
Cambridge, UK and Indianapolis, US – 15 December 2020: Acacia Pharma Group plc (“Acacia Pharma”, the “Group” or the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures or cancer chemotherapy, announces an amendment to the terms of its investment agreement with Cosmo Technologies Ltd, a wholly-owned subsidiary of Cosmo Pharmaceuticals N.V. (“Cosmo”) dated 10 January 2020
Correction: Acacia Pharma Announces Amendment of its Investment Agreement with Cosmo Pharmaceuticals for BYFAVO™ Acacia Pharma Group plc Cambridge, UNITED KINGDOM
Issue price of new ordinary shares to Cosmo in para 8 should be in EUROS rather than GBP and details of Cosmo’s holding post the issue has been added as a final para
Correction - Acacia Pharma Announces Amendment of its Investment Agreement with Cosmo Pharmaceuticals for BYFAVO™
€5 million commercialization milestone to be paid by Acacia Pharma to Cosmo in New Ordinary Shares
BYFAVO expected to be launched in the United States within the coming weeks
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014.
Correction: Acacia Pharma Announces Amendment of its Investment Agreement with Cosmo Pharmaceuticals for BYFAVO™
Issue price of new ordinary shares to Cosmo in para 8 should be in EUROS rather than GBP and details of Cosmo’s holding post the issue has been added as a final para
Correction – Acacia Pharma Announces Amendment of its Investment Agreement with Cosmo Pharmaceuticals for BYFAVO™
€5 million commercialization milestone to be paid by Acacia Pharma to Cosmo in New Ordinary Shares
BYFAVO expected to be launched in the United States within the coming weeks
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014.